<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855359</url>
  </required_header>
  <id_info>
    <org_study_id>SGN19A-004</org_study_id>
    <nct_id>NCT02855359</nct_id>
  </id_info>
  <brief_title>Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma</brief_title>
  <official_title>An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination
      with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse
      large B-cell lymphoma or follicular lymphoma Grade 3b.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A of the study, patients will be randomized 1:1 to receive denintuzumab mafodotin
      plus RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or
      denintuzumab mafodotin plus RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
      to assess the safety of these 2 combination regimens. Part B of the study is designed to
      evaluate the antitumor activity and safety of denintuzumab mafodotin in combination with
      either RCHOP or RCHP (Experimental Arm) compared with RCHOP alone (Comparator Arm).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part B Outcome Measure: Complete Response Rate (CR)</measure>
    <time_frame>Up to 6 months. (Six 21 day cycles plus 30 days for End of Treatment (EOT) Visit.)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A and Part B Outcome Measure: Incidence of adverse events</measure>
    <time_frame>Up to 6 months. (Six 21 day cycles plus 30 days for End of Treatment (EOT) Visit.)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A and Part B Outcome Measure: Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 6 months. (Six 21 day cycles plus 30 days for End of Treatment (EOT) Visit.)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) between study arms in Part B.</measure>
    <time_frame>Up to approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) between study arms in Part B.</measure>
    <time_frame>Up to approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) between study arms in Part B.</measure>
    <time_frame>Up to approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) at End Of Treatment (EOT) between study arms in Part B.</measure>
    <time_frame>Up to 6 months. (Six 21 day cycles plus 30 days for End of Treatment (EOT) Visit.)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response and of complete response (CR) between study arms in Part B.</measure>
    <time_frame>Up to approximately 4 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Diffuse, Large B-Cell, Lymphoma</condition>
  <condition>Follicular Lymphoma, Grade 3b</condition>
  <condition>Transformed Lymphoma / DLBCL</condition>
  <arm_group>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>denintuzumab mafodotin + RCHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denintuzumab mafodotin</intervention_name>
    <description>SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles</description>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles</description>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
    <arm_group_label>RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles</description>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
    <arm_group_label>RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles</description>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
    <arm_group_label>RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)</description>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
    <arm_group_label>RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles</description>
    <arm_group_label>denintuzumab mafodotin + RCHOP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHP</arm_group_label>
    <arm_group_label>denintuzumab mafodotin + RCHOP or RCHP</arm_group_label>
    <arm_group_label>RCHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naive patients with histologically confirmed systemic de novo or
             transformed diffuse large B-cell lymphoma (DLBCL) (from follicular or marginal zone
             lymphoma), or follicular lymphoma (FL) Grade 3b;

               -  patients must have high intermediate or high risk disease

          -  Tumor tissue available from most recent biopsy to determine cell of origin

          -  Fluorodeoxyglucose-avid disease by positron emission tomography and measurable
             disease greater than 1.5cm diameter

          -  Eastern Cooperative Oncology Group performance status â‰¤2

          -  Age 18 years or older

          -  Adequate study baseline laboratory parameters

        Exclusion Criteria:

          -  Previous history of treated indolent lymphoma

          -  History of another primary invasive cancer, hematologic malignancy, or
             myelodysplastic syndrome that has not been in remission for at least 3 years

          -  History of progressive multifocal leukoencephalopathy

          -  Cerebral/meningeal disease related to the underlying malignancy

          -  Patients with the following ocular conditions: corneal disorders, monocular vision
             (ie. best corrected visual acuity greater than or equal to 20/200 in one eye), or
             active ocular disorders requiring treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Kostic, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leilani Jesse, PRA Project Manager</last_name>
    <phone>913-410-2597</phone>
    <email>jesseleilani@prahs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Bernards Cancer Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Moon</last_name>
      <phone>870-207-8177</phone>
      <email>mmonte@sbrmc.org</email>
    </contact>
    <investigator>
      <last_name>Marc Monte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Ortega</last_name>
      <phone>626-218-0563</phone>
      <email>ricortega@coh.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital Harmony Campus</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Gutting</last_name>
      <phone>970-297-6150</phone>
      <email>oncresearch.north@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Georgia Cancer Care</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Kerr</last_name>
      <phone>478-743-7068</phone>
      <phone_ext>262</phone_ext>
      <email>jkerr@centralgacancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Sumrall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Haycraft</last_name>
      <phone>502-899-3366</phone>
      <phone_ext>187</phone_ext>
      <email>dana.haycraft@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Don Stevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montgomery Cancer Center</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Jones</last_name>
      <phone>859-499-1000</phone>
      <email>mcc_research@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Muhammed-Ali Zaydan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-9466</phone>
      <email>laura.rockwell@allina.com</email>
    </contact>
    <investigator>
      <last_name>Michaela Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic (Forrest General Hospital)</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy McBeth</last_name>
      <phone>601-261-1700</phone>
      <email>tmcbeth@forrestgeneral.com</email>
    </contact>
    <investigator>
      <last_name>John Hrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie Mestas</last_name>
      <phone>505-564-6874</phone>
      <email>rosemarie@sjonc.com</email>
    </contact>
    <investigator>
      <last_name>Sadar Imam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirstie Armstrong</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>209</phone_ext>
      <email>karmstrong@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology / Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Cardona</last_name>
      <phone>615-329-7236</phone>
      <email>tiffany.cardona@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Health - Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Townsend</last_name>
      <phone>214-818-8472</phone>
      <email>grace.townsend@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Moshe Yair Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital - Temple</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Strakos</last_name>
      <phone>254-724-1291</phone>
      <email>theresa.strakos@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Vinit Karur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vista Oncology INC PS</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Zhang</last_name>
      <phone>360-352-2900</phone>
      <email>ericz@vista-oncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Kadoun</last_name>
      <phone>253-428-8752</phone>
      <email>dkadoun@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Moacyr de Oliveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Perez</last_name>
      <phone>787-840-2575</phone>
      <phone_ext>4249</phone_ext>
      <email>dperez@psm.edu</email>
    </contact>
    <investigator>
      <last_name>Anna DiMarco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>July 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>SGN-19A</keyword>
  <keyword>Denintuzumab Mafodotin</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antigens, CD19</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Monomethyl auristatin F</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Transformed Lymphoma / DLBCL</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Liposomal doxorubicin</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Alkylating Agents</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Antibiotic, Antineoplastic</keyword>
  <keyword>Antimitotic Agents</keyword>
  <keyword>Antineoplastic Agents, Alkylating</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Phytogenic Antirheumatic Agents</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Follicular Lymphoma Grade 3b</keyword>
  <keyword>immunosuppressive agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
